All In Biotech

Drug Trial Radar · NCT01341353

Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China

Atrial Fibrillation Therapy: A Multi-Center Clinical Study

Last checked: Nov 20, 2026Latest source record: Apr 25, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,800

Planned (sponsor's estimate)

Start

Apr 2011

Primary completion

Dec 2014

Study completion Dec 2015

Sponsor

Lead sponsor
Wuhan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Capital Medical University; Peking Union Medical College; Guangdong Provincial People's Hospital; Nanjing Medical University; West China Hospital; Dalian Medical University; Shanghai Chest Hospital
First posted
Apr 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.

Conditions

  • Atrial Fibrillation

Interventions

  • catheter ablationProcedure

    circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation

  • Digaoxin,amiodarone,β receptor antagonist, Calcium AntagonistsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with all-cause deathTime frame: 3 month
  2. Number of participants with all-cause deathTime frame: 12 month
  3. Number of participants with all-cause deathTime frame: 24 month
  4. Number of participants with all-cause deathTime frame: 36 month
  5. severe blooding complicationsTime frame: 3 month
  6. severe blooding complicationsTime frame: 12 month
  7. severe blooding complicationsTime frame: 24 month
  8. severe blooding complicationsTime frame: 36 month
  9. cardio-cerebrovascular complicationsTime frame: 3 month
  10. cardio-cerebrovascular complicationsTime frame: 12 month
  11. cardio-cerebrovascular complicationsTime frame: 24 month
  12. cardio-cerebrovascular complicationsTime frame: 36 month
  13. Number of participants with cardiovascular death eventsTime frame: 3 month
  14. Number of participants with cardiovascular death eventsTime frame: 12 month
  15. Number of participants with cardiovascular death eventsTime frame: 24 month
  16. Number of participants with cardiovascular death eventsTime frame: 36 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.